Johnson Floats ‘Right To Try 2.0’ As Makary Defends FDA’s Approval Standards

Why It Matters

A legislative shift could accelerate market entry for niche therapies, altering biotech investment dynamics while raising safety oversight concerns for the FDA.

Key Takeaways

• Johnson pushes “Right to Try 2.0” for rare disease drugs.
• Makary cites data gaps behind recent FDA rejections.
• Proposal could bypass standard clinical trial requirements.
• Industry fears reduced safety oversight and liability risks.
• Congressional action may pressure FDA to alter timelines.

Pulse Analysis

The original Right‑to‑Try law, passed in 2014, allowed terminally ill patients to access investigational drugs after Phase I trials, but it left many therapies out of reach due to narrow eligibility criteria. Senator Johnson’s “2.0” concept seeks to broaden that scope, potentially covering earlier‑stage candidates and a wider patient pool. Proponents argue that for ultra‑rare conditions, conventional trial timelines are impractical, and patients should not wait years for experimental options. Critics warn that expanding access without robust data could undermine the evidentiary foundation that underpins drug safety and efficacy assessments.

FDA Commissioner Martin Makary emphasizes that recent denials of high‑profile treatments—particularly gene‑editing and cell‑based therapies—reflect gaps in trial data, not an institutional reluctance to approve innovative products. The agency’s rigorous statistical thresholds, post‑marketing surveillance plans, and manufacturing controls are designed to protect patients while still fostering innovation. Makary’s stance underscores a broader regulatory philosophy: accelerated pathways, such as Breakthrough Therapy and Regenerative Medicine Accelerated Approval, already exist; the challenge lies in ensuring that data quality keeps pace with speed.

If Congress adopts a Right‑to‑Try 2.0 framework, biotech firms could see a shortened path to market, potentially boosting valuations for companies developing orphan drugs. However, investors must weigh the risk of heightened liability and possible post‑approval safety issues that could trigger costly recalls or litigation. For patients, the promise of earlier access is compelling, yet it may come with increased uncertainty about outcomes. Ultimately, the outcome of this policy tug‑of‑war will influence how quickly life‑saving therapies reach those in need and how the FDA balances its dual roles as a gatekeeper and an enabler of medical innovation.